Ladislav Sivak
Brno, JM 61300, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
N-(5-(2-morpholino-4-oxo-3,4-dihydroquinazolin-8-yl)pyridin-2-yl)acylamides as novel multi-PI3K/DNA-PK/P-gp inhibitors for efficient chemosensitization and MDR alleviation.
Journal: European journal of medicinal chemistry
Published: February 16, 2025
In vivo evaluation of selenium-tellurium based nanoparticles as a novel treatment for bovine mastitis.
Journal: Journal of animal science and biotechnology
Published: July 17, 2024
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells.
Journal: Biomarker research
Published: March 12, 2024
Engineered human H-chain ferritin with reversed charge of the internal cavity exhibits RNA-mediated spongelike effect for loading RNA/DNA-binding molecules.
Journal: Biomaterials science
Published: January 22, 2024
Neutrophils in Cancer immunotherapy: friends or foes?
Journal: Molecular cancer
Published: January 09, 2024
Proteinase-activated Receptor 2: Springboard of Tumors.
Journal: Anticancer research
Published: October 28, 2023
Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK).
Journal: Journal of enzyme inhibition and medicinal chemistry
Published: July 25, 2023
BODIPY-labelled acetylcholinesterase reactivators can be encapsulated into ferritin nanovehicles for enhanced bioavailability in the CNS.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 01, 2023
Platinum-based drug-induced depletion of amino acids in the kidneys and liver.
Journal: Frontiers in oncology
Published: July 17, 2022
Simultaneous Delivery of Doxorubicin and Protease Inhibitor Derivative to Solid Tumors via Star-Shaped Polymer Nanomedicines Overcomes P-gp- and STAT3-Mediated Chemoresistance.
Journal: Biomacromolecules
Published: May 18, 2022
Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 11, 2020
Last Updated: 09/26/2026